H1N1 (swine flu) & the R&D-based Pharmaceutical Industry
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
This joint white paper recommends the implementation of well-designed NFC systems coupled with legislative liability protections for pandemic vaccines to ensure both equitable compensation and adequate vaccine coverage in a future pandemic.
Read moreOn 22 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 10: WHO Pathogen Access and Benefit Sharing System, with the Pandemic Influenza Preparedness Framework as an example” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read moreOn 20 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 7: Access to technology: promoting sustainable and equitably distributed production sustainable and equitably distributed production and transfer of technology and know-how” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read more